Studies show that about 60 percent of cancer patients do not respond effectively to chemotherapy treatments – health

Studies show that about 60 percent of cancer patients do not respond effectively to chemotherapy treatments – health

Approximately 60 percent of all cancer patients do not respond effectively to chemotherapy treatment, as estimated by scientists at Purdue University. In recent research, they say the results can be worse – as many of those patients experience toxic and sometimes fatal side effects.

Now, scientists and entrepreneurs at a Purdue University are working to use simple LED lighting to help determine if certain chemotherapy options will work for specific patients. The work is published in the scientific report. “We’re using the same technology as the Doppler radar used in weather to advance personalized medicine,” David Nolte, Edward M. — Awarded Distinguished Professor of Physics and Astronomy at Purdue College of Science. “We take the LED light and shine it on a biopsy. We then apply chemotherapy for biopsy and analyze how light is cut from tissues. “

Nolte, who is also a member of the Purdue University Center for Cancer Research, said the dynamics of light scattering gives scientists and doctors detailed information about the potential for a chemotherapy drug to be effective for a patient. Nolte said he had the results within 24 hours. This first trial looked at biodynamic imaging on human patients with ovarian cancer.

“We look for signs of apoptosis, or what we call controlled death of cells,” Nolte said. “Apoptosis is a sign that indicates the effectiveness of chemotherapy for the tissues and tumors of this patient. For some cancers, there are plenty of treatment options available, such as a doctor trying to fit square pegs into the square hole until the desired result is achieved. We want to improve this process for patients. “

Nolte has worked with Purdue Entrepreneur and several groups within the commercialization ecosystem, including Purdue Foundry, on business plan development and management discoveries. AniDyn, a medical technology startup, was sourced from professors Nolte and John J. Turek from Purdue. AnDDyn focuses on the development and commercialization of live-tissue imaging platform technologies.

Nolte works closely with the Purdue Research Foundation Office of Technology Commercialization to patent and license its technologies.

(This story is published from a wire agency feed without textual modifications.)

Follow more stories at Facebook And Twitter


Leave a Reply

Your email address will not be published. Required fields are marked *